Table 5

Univariate sensitivity analyses of fesoterodine versus tolterodine ER or solifenacin

Assumption changed

Fesoterodine ICER relative to:


Tolterodine

Solifenacin


Base-case scenario: Results weeks 52, societal perspective

Cost-savings

Cost-savings

Weeks 52, health system perspective

Cost-savings

Cost-savings

Weeks 12, health system perspective

€574

€14,568

Weeks 12, societal perspective

€9,106

€216,316

+/- 25% in OAB-related co morbidities costs

Cost-savings

Cost-savings

+/- 25% in OAB-related co morbidities rate per year in continent patients

Cost-savings

Cost-savings

+/- 25% in OAB-related co morbidities rate per year in incontinent patients

Cost-savings

Cost-savings

+/- 25% in utility estimates

Cost-savings

Cost-savings

+/- 25% in % of responders to fesoterodine 4 mg and solifenacin 5 mg that titrate to the higher dose at week 4

Cost-savings

Cost-savings

+/- 25% in % of non-responders to fesoterodine 4 mg and solifenacin 5 mg that do not to titrate to the higher dose at week 4

Cost-savings

Cost-savings

+25% in % continent patients at week 12

Cost-savings

Cost-savings

- 25% in % continent patients at week 12

€39,447

€17,814

+/- 25% in % continent patients at week 52

Cost-savings

Cost-savings

+/- 25% in medical services costs*

Cost-savings

Cost-savings

Medical services utilization

Cost-savings

Cost-savings

+/- 25% % of incontinent patients using pads

Cost-savings

Cost-savings

+/- 25% No. pads/day for incontinent patients

Cost-savings

Cost-savings

+/- 25% in # GP visits/month

Cost-savings

Cost-savings

+/- 25% in # specialist visits/month

Cost-savings

Cost-savings

+/- 25% in # lab tests/month

Cost-savings

Cost-savings

Productivity data

Cost-savings

Cost-savings

+/- 25% in decrease in hours worked due to incontinence

Cost-savings

Cost-savings

+/- 25% in reduced daytime productivity due to nocturia

Cost-savings

Cost-savings

+/- 25% in % employed in population

Cost-savings

Cost-savings

+/- 25% in average hourly wage

Cost-savings

Cost-savings


ICER = Incremental Cost-effectiveness Ratio. *Costs of incontinence pads, general practitioners visits, specialist visits, laboratory tests and constipation cost/day.

Arlandis-Guzman et al. BMC Urology 2011 11:9   doi:10.1186/1471-2490-11-9

Open Data